Skip to main content

Many protective safety measures are in place to help ensure our plasma collection centers are safe during the COVID-19 crisis. A thorough screening is also conducted to ensure you can donate. Find out more

CSL Plasma Reimagines Donor Experience With First Donations Completed on Innovative Plasma Collection Technology

New technology is designed to reduce collection time and improve donor experience; Aurora, Colorado, location is first of 300-plus CSL Plasma U.S. centers to convert to Rika Plasma Donation System

news

plasma donor donates on new technology

BOCA RATON, FLORIDA – 4 AUGUST 2022 – CSL Plasma, the plasma collection business of global biotherapeutics leader CSL Behring, today began a new era in plasma donations, collecting its first plasma donations using leading-edge plasma collection technology that is expected to significantly reduce average collection time – by approximately one-third – and improve the donor experience. 

The Rika Plasma Donation System, only available at CSL Plasma and developed by Terumo Blood and Cell Technologies, is designed to reduce collection time, and improve the donor and operator experience. When considering prior average CSL Plasma donation procedure times, this could represent about a 30% reduction in average donation time for donors.

The new plasmapheresis system first launched today in the Aurora, Colorado, CSL Plasma location, as part of a phased rollout to CSL Plasma U.S. collection centers. Plasma collected at CSL Plasma facilities is used in the manufacturing of lifesaving plasma-derived therapies.

“Today marks a threshold moment for plasma donors following years of dedication, innovation and collaboration – demonstrating how we are driven by our promise in delivering lifesaving and life-extending therapies to patients around the world,” said CSL Chief Operating Officer Paul McKenzie. “We look forward to the positive impact this new technology brings and are thankful for plasma donors who continue to do the amazing every day when they donate at CSL Plasma.”

CSL Plasma believes features of the new Rika system can enable the collection of more plasma, in shorter periods of time, supporting quality and safety, and, ultimately, better serving patients who rely on plasma-based therapies.

One of the first plasma donors to experience the Rika system, Kelly Geiser is a resident of the Denver area. She has donated plasma since 2017, and is a Platinum level donor as part of CSL Plasma’s donor loyalty program, iGive Rewards®.

Geiser appreciated that she was able to complete the donation procedure with the new technology in under 35 minutes and in the fastest donation time she has experienced, while every plasma donor’s experience will vary. Donating plasma is also personal for Geiser, who says that therapies made from plasma have helped her and her family, including a parent who recently underwent emergency surgery.

“It feels good knowing I’m helping people and, who knows, I might’ve helped somebody I know,” said Geiser.

According to Terumo BCT, benefits of the Rika Plasma Donation System include: 

  • Rika completes one plasma collection in 35 minutes or less on average. The proprietary design of the system's centrifuge maximizes the plasma yield per cycle.
  • The Rika Plasma Donation System was designed to allow no more than 200 milliliters of blood cells outside the donor’s body, resulting in a low extracorporeal volume, which may contribute to a more comfortable donor experience.
  • With less than 200 milliliters of blood cells outside the donor’s body at any given time, should the initial procedure not be completed, the donor can return and donate without being deferred.

The device is designed with an advanced user interface to guide CSL Plasma front-line employees. Operators can quickly and confidently resolve alarms, thanks to guidance provided on the Rika system's touchscreen, which also alerts operators about situations that require attention and provides suggested actions to resolve the situation. The system allows for real-time data analytics to drive device maintenance and repairs. 

CSL Plasma is implementing the new devices at Colorado centers and then expanding to other U.S. locations, providing donors more opportunities to “do the amazing” and be rewarded for their generosity.

“As a long-time leader in our industry, CSL Plasma looks forward to this new plasmapheresis technology to delight our plasma donors and attract new donors while supporting a better operating experience for our employees,” said Walter Charles, CSL Plasma Senior Vice President and General Manager. “As we complete the implementation of new technology at U.S. centers, we continue to address the critical and ongoing need for human plasma to produce life-saving medicines for people with serious and rare diseases.”

About CSL Plasma
CSL Plasma operates one of the world’s largest and most sophisticated plasma collection networks, with more than 300 plasma collection centers in the U.S., Europe and China. Headquartered in Boca Raton, Florida, CSL Plasma is a subsidiary of CSL Behring, a global biotherapeutics company and a member of the CSL Group of companies. Plasma collected at CSL Plasma facilities is used by CSL Behring for the sole purpose of manufacturing lifesaving plasma-derived therapies for people in more than 100 countries. The parent company, CSL Limited (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 25,000 people. For more information about CSL Plasma visit, www.cslplasma.com.

About CSL Behring
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives.

For inspiring stories about the promise of biotechnology, visit CSLBehring.com/Vita and follow us on Twitter.com/CSLBehring.

Media Contact in U.S.

Rhonda Sciarra

Director, Communications, CSL Plasma 

Office: + 1 561 981 4207

Mobile: +1 551 228 3244

rhonda.sciarra@cslplasma.com


Media Contact in Australia

Jimmy Baker

Senior Communications Business Partner, CSL

+61 450 909 211

jimmy.baker@csl.com.au